Is Modern Shoulder Technology Worth the Cost?

Do advancements in shoulder arthroplasty technology provide improvements in value to patients?

In the world of modern medicine, new technology is often synonymous with higher costs, and there is a constant debate whether these innovations provide meaningful improvements in clinical outcomes. To analyze this, Roche and colleagues conducted a longitudinal study of 6,042 patients over a 15-year period. They wanted to objectively measure “value,” defined as the quality of the outcome divided by the cost of the implant. The study tracked the adoption of several major innovations, including intraoperative computer navigation, augmented glenoids, hybrid glenoids, stemless implants and short stems, to see if these new technologies actually move the needle for patients without increasing the burden on the healthcare system.

• Rising value for reverse shoulder arthroplasty (rTSA): The value of reverse shoulder surgery significantly increased over the 15-year study period because clinical outcomes improved with the introduction/adoption of new technologies, while implant prices actually dropped.
• Consistently high value for anatomic shoulder arthroplasty (aTSA): aTSA value remained steady and high, consistently outperforming rTSA over the 15-year study period in terms of the outcome-to-cost ratio.
• Improved radiographic results: New technologies like hybrid aTSA glenoids led to a significant decrease in radiolucent lines compared to legacy designs.
• Major efficiency gains: The average hospital stay dropped from over 3.5 days in 2007 to <24 hours in 2021, implying shoulder patients have had a reduced burden over time on the healthcare system.
• Rapid adoption of new technology: By 2021, the vast majority of aTSA and rTSA procedures utilized preoperative planning and navigation, reflecting a massive shift in surgical decision making and adoption.

The data suggests that innovation has successfully created value without burdening payers; as implant prices declined or stayed flat, clinical outcomes reached new heights. New technologies, like preoperative planning and navigation, have made these excellent results more reproducible, even as surgeons treat an increasingly complex patient population, with the help of new technologies like augmented glenoids.

These findings are limited because the cost analysis only included U.S. implant selling prices and did not incorporate surgeon fees, hospital overhead or the costs of physical therapy.